Refining Efficacy. Exploiting Functional Selectivity for Drug Discovery

Advances in Pharmacology

Volumn 62, Issue , 2011, Pages 79-107

  Gesty Palmer, Diane ^a   Luttrell, Louis M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Arrestin; Bone remodeling; Functional selectivity; G protein coupled receptor; Parathyroid hormone; Type 1 parathyroid hormone receptor

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE; CARVEDILOL; G PROTEIN COUPLED RECEPTOR; MK 0354; NEUROLEPTIC AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE[1-31]; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[1-38]; PARATHYROID HORMONE[2-34]; PARATHYROID HORMONE[2-38]; PARATHYROID HORMONE[28-42]; PARATHYROID HORMONE[28-48]; PARATHYROID HORMONE[3-34]; PARATHYROID HORMONE[3-38]; PARATHYROID HORMONE[7-34]; PROPRANOLOL; RETINA S ANTIGEN; UNCLASSIFIED DRUG;

AGONIST; BOOK; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HEART FAILURE; HUMAN; HYPERCALCEMIA; HYPERLIPIDEMIA; LIGAND BINDING; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

EID: 80052686988     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385952-5.00009-9     Document Type: Chapter

References (146)

1. Abou-Samra A.B., Juppner H., Force T., Freeman M.W., Kong X.F., Schipani E., et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:2732-2736.
2. Ahn S., Kim J., Hara M.R., Ren X.R., Lefkowitz R.J. Beta-arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. The Journal of Biological Chemistry 2009, 284:8855-8865.
3. Ahn S., Shenoy S.K., Wei H., Lefkowitz R.J. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. The Journal of Biological Chemistry 2004, 279:35518-35525.
4. Angers S., Salahpour A., Bouvier M. Dimerization: An emerging concept for G protein-coupled receptor ontogeny and function. Annual Review of Pharmacology and Toxicology 2002, 42:409-435.
5. Aplin M., Christensen G.L., Schneider M., Heydorn A., Gammeltoft S., Kjølbye A.L., et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic & Clinical Pharmacology & Toxicology 2007, 100:296-301.
6. Armamento-Villareal R., Ziambaras K., Abbasi-Jarhomi S.H., Dimarogonas A., Halstead L., Fausto A., et al. An intact N terminus is required for the anabolic action of parathyroid hormone on adult female rats. Journal of Bone and Mineral Research 1997, 12:384-392.
7. Azarani A., Goltzman D., Orlowski J. Structurally diverse N-terminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) inhibit the Na+/H+ exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activating distinct signaling pathways. The Journal of Biological Chemistry 1996, 271:14931-14936.
8. Azzi M., Charest P.G., Angers S., Rousseau G., Kohout T., Bouvier M., et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:11406-11411.
9. Barlic J., Andrews J.D., Kelvin A.A., Bosinger S.E., DeVries M.E., Xu L., et al. Regulation of tyrosine kinase activation and granule release through beta-arrestin by CXCRI. Nature Immunology 2000, 1:227-233.
10. Beaulieu J.M., Marion S., Rodriguiz R.M., Medvedev I.O., Sotnikova T.D., Ghisi V., et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 2008, 132:125-136.
11. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
12. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:5099-5104.
13. Berg K.A., Maayani S., Goldfarb J., Scaramellini C., Leff P., Clarke W.P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Molecular Pharmacology 1998, 54:94-104.
14. Bhattacharya M., Anborgh P.H., Babwah A.V., Dale L.B., Dobransky T., Benovic J.L., et al. Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization. Nature Cell Biology 2002, 4:547-555.
15. Bisello A., Chorev M., Rosenblatt M., Monticelli L., Mierke D.F., Ferrari S.L. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. The Journal of Biological Chemistry 2002, 277:38524-38530.
16. Bisello A., Horwitz M.J., Stewart A.F. Parathyroid hormone-related protein: An essential physiological regulator of adult bone mass. Endocrinology 2004, 145:3551-3553.
17. Bisello A., Manen D., Pierroz D.D., Usdin T.B., Rizzoli R., Ferrari S.L. Agonist-specific regulation of parathyroid hormone (PTH) receptor type 2 activity: Structural and functional analysis of PTH- and tuberoinfundibular peptide (TIP) 39-stimulated desensitization and internalization. Molecular Endocrinology 2004, 18:1486-1498.
18. Black J.W., Leff P. Operational models of pharmacological agonist. Proceedings of the Royal Society B: Biological Sciences 1983, 220:141-162.
19. Black J.W., Leff P., Shankley N.P. An operational model of pharmacological agonism: The effect of E/[A] curve shape on agonist dissociation constant estimation. British Journal of Pharmacology 1985, 84:561-571.
20. Bockaert J., Marin P., Dumuis A., Fagni L. The 'magic tail' of G protein-coupled receptors: An anchorage for functional protein networks. FEBS Letters 2003, 546:65-72.
21. Bohn L.M., Lefkowitz R.J., Caron M.G. Differential mechanisms of morphine antinociceptive tolerance revealed in beta-arrestin-2 knock-out mice. The Journal of Neuroscience 2002, 22:10494-10500.
22. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., Lin F.-T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-2498.
23. Bouxsein M.L., Pierroz D.D., Glatt V., Goddard D.S., Cavat F., Rizzoli R., et al. Beta-arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. Journal of Bone and Mineral Research 2005, 20:635-643.
24. Brady A.E., Limbird L.E. G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction. Cellular Signalling 2002, 14:297-309.
25. Bringhurst F.R., Juppner H., Guo J., Urena P., Potts J.T., Kronenberg H.M., et al. Cloned, stably expressed parathyroid hormone (PTH)/PTH-related peptide receptors activate multiple messenger signals and biological responses in LLC-PK1 kidney cells. Endocrinology 1993, 132:2090-2098.
26. Christensen G.L., Kelstrup C.D., Lyngso C., Sarwar U., Bogebo R., Sheikh S.P., et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Molecular & Cellular Proteomics 2010, 9:1540-1553.
27. Cordeaux Y., Briddon S.J., Megson A.E., McDonnell J., Dickenson J.M., Hill S.J. Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: Evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. Molecular Pharmacology 2000, 58:1075-1084.
28. Costa T., Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:7321-7325.
29. Dean T., Vilardaga J.P., Potts J.T., Gardella T.J. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Molecular Endocrinology 2008, 22:156-166.
30. DeFea K.A., Vaughn Z.D., O'Bryan E.M., Nishijima D., Dery O., Bunnett N.W. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:11086-11091.
31. DeFea K.A., Zalevsky J., Thoma M.S., Dery O., Mullins R.D., Bunnett N.W. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. The Journal of Cell Biology 2000, 148:1267-1281.
32. Devi L. Heterodimerization of G-protein-coupled receptors: Pharmacology, signaling and trafficking. Trends in Pharmacological Sciences 2001, 22:532-537.
33. DeWire S.M., Kim J., Whalen E.J., Ahn S., Chen M., Lefkowitz R.J. Beta-arrestin-mediated signaling regulates protein synthesis. The Journal of Biological Chemistry 2008, 283:10611-10620.
34. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995, 136:3632-3638.
35. Drake M.T., Violin J.D., Whalen E.J., Wisler J.W., Shenoy S.K., Lefkowitz R.J. Beta-arrestin-biased agonism at the beta2-adrenergic receptor. The Journal of Biological Chemistry 2008, 283:5669-5676.
36. Ehlert F.J. Analysis of allosterism in functional assays. The Journal of Pharmacology and Experimental Therapeutics 2005, 315:740-754.
37. Evans B.N., Rosenblatt M.I., Mayer L.O., Oliver K.R., Dickerson I.M. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. The Journal of Biological Chemistry 2000, 275:31438-31443.
38. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: The role in receptor desensitization and signaling. Pharmacological Reviews 2001, 53:1-24.
39. Ferrandon S., Feinstein T.N., Castro M., Wang B., Bouley R., Potts J.T., et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nature Chemical Biology 2009, 5:734-742.
40. Ferrari S.L., Behar V., Chorev M., Rosenblatt M., Bisello A. Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves beta-arrestin2. Real-time monitoring by fluorescence microscopy. The Journal of Biological Chemistry 1999, 274:29968-29975.
41. Ferrari S.L., Bisello A. Cellular distribution of constitutively active mutant parathyroid hormone (PTH)/PTH-related protein receptors and regulation of cyclic adenosine 3',5'-monophosphate signaling by β-arrestin2. Molecular Endocrinology 2001, 15:149-163.
42. Ferrari S.L., Bouxsein M.L. Beta-arrestin-biased parathyroid hormone ligands: A new approach to the development of agents that stimulate bone formation. Science Translational Medicine 2009, 1:1ps1.
43. Ferrari S.L., Pierroz D.D., Glatt V., Goddard D.S., Bianchi E.N., Lin F.T., et al. Bone response to intermittent parathyroid hormone is altered in mice null for beta-arrestin2. Endocrinology 2005, 146:1854-1862.
44. Foord S.M., Marshall F.H. RAMPs: Accessory proteins for seven transmembrane domain receptors. Trends in Pharmacological Sciences 1999, 20:184-187.
45. Friedman P.A., Gesek F.A., Morley P., Whitfield J.F., Willick G.E. Cell specific signaling and structure-activity relations of parathyroid hormone analogs in mouse kidney cells. Endocrinology 1999, 140:301-309.
46. Galandrin S., Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Molecular Pharmacology 2006, 70:1575-1584.
47. Gardella T.J., Jüppner H. Interaction of PTH and PTHrP with their receptors. Reviews in Endocrine & Metabolic Disorders 2000, 1:317-329.
48. Gardella T.J., Luck M.D., Jensen G.S., Schipani E., Potts J.T., Juppner H. Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology 1996, 137:3936-3941.
49. Ge L., Ly Y., Hollenberg M., DeFea K. A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. The Journal of Biological Chemistry 2003, 278:34418-34426.
50. George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., et al. Oligomerization of μ- and δ-opioid receptors. Generation of novel functional properties. The Journal of Biological Chemistry 2000, 275:26128-26135.
51. Gesty-Palmer D., Chen M., Reiter E., Ahn S., Nelson C.D., Wang S., et al. Distinct conformations of the parathyroid hormone receptor mediate G protein and beta-arrestin dependent activation of ERK1/2. The Journal of Biological Chemistry 2006, 281:10856-10864.
52. Gesty-Palmer D., Flannery P., Yuan L., Corsino L., Spurney R., Lefkowitz R.J., et al. A beta-arrestin biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Science Translational Medicine 2009, 1:1ra1.
53. Gether U., Lin S., Kobilka B.K. Fluorescent labeling of purified β2 adrenergic receptor. Evidence for ligand-specific conformational changes. The Journal of Biological Chemistry 1995, 270:28268-28275.
54. Ghanouni P., Gryczynski Z., Steenhuis J.J., Lee T.W., Farrens D.L., Lakowicz J.R., et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. The Journal of Biological Chemistry 2001, 276:24433-24436.
55. Gong H., Sun H., Koch W.J., Rau T., Eschenhagen T., Ravens U., et al. Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation 2002, 105:2497-2503.
56. Goodman O.B., Krupnick J.G., Santini F., Gurevich V.V., Penn R.B., Gagnon A.W., et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 1996, 383:447-450.
57. Gurwitz D., Haring R., Heldman E., Fraser C.M., Manor D., Fisher A. Discrete activation of transduction pathways associated with acetylcholine M1 receptor by several muscarinic ligands. European Journal of Pharmacology 1994, 267:21-31.
58. Hilliker S., Wergedal J.E., Gruber H.E., Bettica P., Baylink D.J. Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo. Bone 1996, 19:469-477.
59. Hilser V.J., Garcia-Moreno E.B., Oas T.G., Kapp G., Whitten S.T. A statistical thermodynamic model of protein ensembles. Chemical Reviews 2006, 106:1545-1558.
60. Hinkle P.M., Sebag J.A. Structure and function of the melanocortin2 receptor accessory protein (MRAP). Molecular and Cellular Endocrinology 2009, 300:25-31.
61. Hock J.M., Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. Journal of Bone and Mineral Research 1992, 7:65-72.
62. Holloway A.C., Qian H., Pipolo L., Ziogas J., Miura S., Karnik S., et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Molecular Pharmacology 2002, 61:768-777.
63. Horwitz M.J., Tedesco M.B., Garcia-Ocaña A., Sereika S.M., Prebehala L., Bisello A., et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: Defining the maximal tolerable dose. The Journal of Clinical Endocrinology and Metabolism 2010, 95:1279-1287.
64. Jafri F., El-Shewy H.M., Lee M.H., Kelly M., Luttrell D.K., Luttrell L.M. Constitutive ERK1/2 activation by a chimeric neurokinin 1 receptor-beta-arrestin1 fusion protein. Probing the composition and function of the G protein-coupled receptor " signalsome" The Journal of Biological Chemistry 2006, 281:19346-19357.
65. Jarpe M.B., Knall C., Mitchell F.M., Buhl A.M., Duzic E., Johnson G.L. [DArg1, D-Phe5, D-Trp7,9, Leu11] Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. The Journal of Biological Chemistry 1998, 273:3097-3104.
66. Jin L.Q., Wang H.Y., Friedman E. Stimulated D(1) dopamine receptors couple to multiple Ga proteins in different brain regions. Journal of Neurochemistry 2001, 78:981-990.
67. Jordan B.A., Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999, 399:697-700.
68. Jouishomme H., Whitfield J.F., Chakravarthy B., Durkin J.P., Gagnon L., Isaacs R.J., et al. The protein kinase-C activation domain of the parathyroid hormone. Endocrinology 1992, 130:53-60.
69. Jouishomme H., Whitfield J.F., Gagnon L., MacLean S., Isaacs R., Chakravarthy B., et al. Further definition of the protein kinase C activation domain of the parathyroid hormone. Journal of Bone and Mineral Research 1994, 9:943-949.
70. Juppner H., Abou-Samra A.B., Freeman M., Kong X.F., Schipani E., Richards J., et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991, 254:1024-1026.
71. Karlin A. On the application of " a plausible model" of allosteric proteins to the receptor for acetylcholine. Journal of Theoretical Biology 1967, 16:306-320.
72. Kenakin T. Agonist-receptor efficacy. II. Agonist-trafficking of receptor signals. Trends in Pharmacological Sciences 1995, 16:232-238.
73. Kenakin T.P. Receptor conformational induction versus selection: All part of the same energy landscape. Trends in Pharmacological Sciences 1996, 17:190-191.
74. Kenakin T. Allosteric agonist modulators. Journal of Receptor and Signal Transduction Research 2007, 27:247-259.
75. Kenakin T., Miller L.E. Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacological Reviews 2010, 62:265-304.
76. Kim J., Ahn S., Ren X.R., Whalen E.J., Reiter E., Wei H., et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:1442-1447.
77. Kobilka B.K., Deupi X. Conformational complexity of G-protein-coupled receptors. Trends in Pharmacological Sciences 2007, 28:397-406.
78. Koh A.J., Beecher C.A., Rosol T.J., McCauley L.K. 3',5'-Cyclic adenosine monophosphate activation in osteoblastic cells: Effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology 1999, 140:3154-3162.
79. Kohout T.A., Nicholas S.L., Perry S.J., Reinhart G., Junger S., Struthers R.S. Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. The Journal of Biological Chemistry 2004, 279:23214-23222.
80. Kudlacek O., Waldoer M., Kassack M.U., Nickel P., Salmi J.I., Freissmuth M., et al. Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: The A1 adenosine receptor is predominantly coupled to Goalpha in human brain. Naunyn Schmiedeberg's Archives of Pharmacology 2002, 365:8-16.
81. Laporte S.A., Oakley R.H., Zhang J., Holt J.A., Ferguson S.S., Caron M.G., et al. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:3712-3717.
82. Laugwitz K.L., Allgeier A., Offermanns S., Spicher K., Van Sande J., Dumont J.E., et al. The human thyrotropin receptor: A heptahelical receptor capable of stimulating members of all four G protein families. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:116-120.
83. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20:612-627.
84. Leach K., Sexton P.M., Christopoulos A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends in Pharmacological Sciences 2007, 28:382-389.
85. Lederer E.D., Sohi S.S., McLeish K.R. Parathyroid hormone stimulates extracellular signal-regulated kinase (ERK) activity through two independent signal transduction pathways: Role of ERK in sodium-phosphate cotransport. Journal of the American Society of Nephrology 2000, 11:222-231.
86. Lee M.-H., El-Shewy H.M., Luttrell D.K., Luttrell L.M. Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription. The Journal of Biological Chemistry 2008, 283:2088-2097.
87. Lefkowitz R.J. G protein-coupled receptor kinases. Cell 1993, 74:409-412.
88. Lin F.-T., Miller W.E., Luttrell L.M., Lefkowitz R.J. Feedback regulation of beta-arrestin1 function by extracellular signal-regulated kinases. The Journal of Biological Chemistry 1999, 274:15971-15974.
89. Livesay D.R., Dallakyan S., Wood G.G., Jacobs D.J. A flexible approach for understanding protein stability. FEBS Letters 2004, 576:468-476.
90. Luttrell L.M., Ferguson S.S., Daaka Y., Miller W.E., Maudsley S., Della Rocca G.J., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999, 283:655-661.
91. Luttrell L.M., Gesty-Palmer D. Beyond desensitization: Physiological relevance of arrestin-dependent signaling. Pharmacological Reviews 2010, 62:305-330.
92. Luttrell L.M., Roudabush F.L., Choy E.W., Miller W.E., Field M.E., Pierce K.L., et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:2449-2454.
93. Lymperopoulos A., Rengo G., Zincarelli C., Kim J., Soltys S., Koch W.J. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:5825-5830.
94. Mahon M.J., Donowitz M., Yun C.C., Segre G.V. Na(+)/H(+) exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signaling. Nature 2002, 417:858-861.
95. Manning D.R. Measures of efficacy using G proteins as endpoints: Differential engagement of G proteins through single receptors. Molecular Pharmacology 2002, 62:451-452.
96. Masri B., Salahpour A., Didriksen M., Ghisi V., Beaulieu J.M., Gainetdinov R.R., et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:13656-13661.
97. Maudsley S., Martin B., Luttrell L.M. The origins of diversity and specificity in G protein-coupled receptor signaling. The Journal of Pharmacology and Experimental Therapeutics 2005, 314:485-494.
98. McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E., Lin F.-T., et al. Beta-arrestin 2: A receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000, 290:1574-1577.
99. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393:333-339.
100. Meller E., Puza T., Diamond J., Lieu H.D., Bohmaker K. Comparative effects of receptor inactivation, 17 β-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro. The Journal of Pharmacology and Experimental Therapeutics 1992, 263:462-469.
101. Miao D., Li J., Xue Y., Su H., Karaplis A.C., Goltzman D. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology 2004, 145:3554-3562.
102. Milligan G. Oligomerisation of G-protein-coupled receptors. Journal of Cell Science 2001, 114:1265-1271.
103. Miura S., Zhang J., Matsuo Y., Saku K., Karnik S.S. Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation. Hypertension Research 2004, 27:65-77.
104. Mohan S., Kutilek S., Zhang C., Shen H.G., Kodama Y., Srivastava A.K. Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone 2000, 27:471-478.
105. Nasman J., Kukkonen J.P., Ammoun S., Akerman K.E. Role of G-protein availability in differential signaling by α2-adrenoceptors. Biochemical Pharmacology 2001, 62:913-922.
106. Nelson C.D., Perry S.J., Regier D.S., Prescott S.M., Topham M.K., Lefkowitz R.J. Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science 2007, 315:663-666.
107. Offermanns S., Wieland T., Homann D., Sandmann J., Bombien E., Spicher K., et al. Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq/11. Molecular Pharmacology 1994, 45:890-898.
108. Okazaki M., Ferrandon S., Vilardaga J.P., Bouxsein M.L., Potts J.T., Gardella T.J. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:16525-16530.
109. Perry S.J., Baillie G.S., Kohout T.A., McPhee I., Magiera M.M., Ang K.L., et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 2002, 298:834-836.
110. Qin L., Raggatt L.J., Partridge N.C. Parathyroid hormone: A double-edged sword for bone metabolism. Trends in Endocrinology and Metabolism 2004, 15:60-65.
111. Rajagopal K., Whalen E.J., Violin J.D., Stiber J.A., Rosenberg P.B., Premont R.T., et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:16284-16289.
112. Sagan S., Chassaing G., Pradier L., Lavielle S. Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors. The Journal of Pharmacology and Experimental Therapeutics 1996, 276:1039-1048.
113. Samama P., Cotecchia S., Costa T., Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. The Journal of Biological Chemistry 1993, 268:4625-4636.
114. Schmidt I., Dobnig H., Turner R. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology 1995, 136:5127-5134.
115. Semple G., Skinner P.J., Gharbaoui T., Shin Y.J., Jung J.K., Cherrier M.C., et al. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. Journal of Medicinal Chemistry 2008, 51:5101-5108.
116. Shenoy S.K., McDonald P.H., Kohout T.A., Lefkowitz R.J. Regulation of receptor fate by ubiquitination of activated β2-adrenergic receptor and β-arrestin. Science 2001, 294:1307-1313.
117. Shimizu N., Dean T., Tsang J.C., Khatri A., Potts J.T., Gardella T.J. Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor. The Journal of Biological Chemistry 2005, 280:1797-1807.
118. Sneddon W.B., Bisello A., Magyar C.E., Willick G.E., Syme C.A., Galbiati F., et al. Ligand-selective dissociation of activation and internalization of the parathyroid hormone receptor. Conditional efficacy of PTH peptide fragments. Endocrinology 2004, 145:2815-2823.
119. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993, 365:170-175.
120. Stewart A.F., Cain R.L., Burr D.B., Jacob D., Turner C.H., Hock J.M. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: A comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. Journal of Bone and Mineral Research 2000, 15:1517-1525.
121. Sullivan S.K., McGrath D.A., Grigoriadis D., Bacon K.B. Pharmacological and signaling analysis of human chemokine receptor CCR-7 stably expressed in HEK-293 cells: High-affinity binding of recombinant ligands MIP-3beta and SLC stimulates multiple signaling cascades. Biochemical and Biophysical Research Communications 1999, 263:685-690.
122. Swaminath G., Xiang Y., Lee T.W., Steenhuis J., Parnot C., Kobilka B.K. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. The Journal Biological Chemistry 2004, 279:686-691.
123. Takasu H., Gardella T.J., Luck M.D., Potts J.T., Bringhurst F.R. Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: Implications for design of signal-specific PTH ligands. Biochemistry 1999, 38:13453-13460.
124. Tam C.S., Heersche J.N., Murray T.M., Parsons J.A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration. Endocrinology 1982, 110:506-512.
125. Thron C.D. On the analysis of pharmacological experiments in terms of an allosteric receptor model. Molecular Pharmacology 1973, 9:1-9.
126. Tohgo A., Pierce K.L., Choy E.W., Lefkowitz R.J., Luttrell L.M. beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. The Journal of Biological Chemistry 2002, 277:9429-9436.
127. Verheijen M.H., Defize L.H. Parathyroid hormone activates mitogen-activated protein kinase via a cAMP-mediated pathway independent of Ras. The Journal of Biological Chemistry 1997, 272:3423-3429.
128. Vilardaga J.P., Krasel C., Chauvin S., Bambino T., Lohse M.J., Nissenson R.A. Internalization determinants of the parathyroid hormone receptor differentially regulate beta-arrestin/receptor association. The Journal of Biological Chemistry 2002, 277:8121-8129.
129. Vilardaga J.P., Romero G., Friedman P.A., Gardella T.J. Molecular basis of parathyroid hormone receptor signaling and trafficking: A family B GPCR paradigm. Cellular and Molecular Life Sciences 2011, 68:1-13.
130. Violin J.D., Dewire S.M., Yamashita D., Rominger D.H., Nguyen L., Schiller K., et al. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. The Journal of Pharmacology and Experimental Therapeutics 2010, 335:572-579.
131. Walters R.W., Shukla A.K., Kovacs J.J., Violin J.D., DeWire S.M., Lam C.M., et al. Beta-arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. The Journal of Clinical Investigation 2009, 119:1312-1321.
132. Wang L., Martin B., Brenneman R., Luttrell L.M., Maudsley S. Allosteric modulators of G protein-coupled receptors: Future therapeutics for complex physiological disorders. The Journal of Pharmacology and Experimental Therapeutics 2009, 331:340-348.
133. Wei H., Ahn S., Shenoy S.K., Karnik S., Hunyady L., Luttrell L.M., et al. Independent G protein and beta-arrestin2 mediated activation of ERK by angiotensin. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:10782-10787.
134. Weinman E.J., Hall R.A., Friedman P.A., Liu-Chen L.Y., Shenolikar S. The association of NHERF adaptor proteins with g protein-coupled receptors and receptor tyrosine kinases. Annual Review of Physiology 2006, 68:491-505.
135. Weiss J.M., Morgan P.H., Lutz M.W., Kenakin T.P. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. Journal of Theoretical Biology 1996, 181:381-397.
136. Whistler J.L., Chuang H.H., Chu P., Jan L.Y., von Zastrow M. Functional dissociation of mu opioid receptor signaling and endocytosis: Implications for the biology of opiate tolerance and addiction. Neuron 1999, 23:737-746.
137. Whistler J.L., von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:9914-9919.
138. Whitfield J.F., Isaacs R.J., Chakravarthy B., Maclean S., Morley P., Willick G., et al. Stimulation of protein kinase C activity in cells expressing human parathyroid hormone receptors by C- and N-terminally truncated fragments of parathyroid hormone 1-34. Journal of Bone and Mineral Research 2001, 16:441-447.
139. Whitfield J.F., Morley P. Small bone-building fragments of parathyroid hormone: New therapeutic agents for osteoporosis. Trends in Pharmacological Sciences 1995, 16:382-386.
140. Wisler J.W., DeWire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., et al. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:16657-16662.
141. Witherow D.S., Garrison T.R., Miller W.E., Lefkowitz R.J. Beta-arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:8603-8607.
142. Xiao K., Sun J., Kim J., Rajagopal S., Zhai B., Villen J., et al. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:15299-15304.
143. Zheng H., Loh H.H., Law P.Y. Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Molecular Pharmacology 2008, 73:178-190.
144. Zhu X., Gilbert S., Birnbaumer M., Birnbaumer L. Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density. Molecular Pharmacology 1994, 46:460-469.
145. Zimmerman B., Simaan M., Lee M.-H., Luttrell L.M., Laporte S.A. c-Src-mediated phosphorylation of AP-2 reveals a general mechanism for receptors internalizing through the clathrin pathway. Cellular Signalling 2009, 21:103-110.
146. Zoudilova M., Kumar P., Ge L., Wang P., Bokoch G.M., DeFea K.A. Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. The Journal of Biological Chemistry 2007, 282:20634-20646.